key: cord-0905959-gw2n8rzq
authors: Kubik, Slawomir; Marques, Ana Claudia; Xing, Xiaobin; Silvery, Janine; Bertelli, Claire; De Maio, Flavio; Pournaras, Spyros; Burr, Tom; Duffourd, Yannis; Siemens, Helena; Alloui, Chakib; Song, Lin; Wenger, Yvan; Saitta, Alexandra; Macheret, Morgane; Smith, Ewan W.; Menu, Philippe; Brayer, Marion; Steinmetz, Lars M.; Si-Mohammed, Ali; Chuisseu, Josiane; Stevens, Richard; Constantoulakis, Pantelis; Sali, Michela; Greub, Gilbert; Tiemann, Carsten; Pelechano, Vicent; Willig, Adrian; Xu, Zhenyu
title: Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples
date: 2021-04-02
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.03.029
sha: a8c57e052eda309506bf703237708624ca841988
doc_id: 905959
cord_uid: gw2n8rzq

OBJECTIVES: SARS-CoV-2 genotyping has been instrumental to monitor viral evolution and transmission during the pandemic. The quality of the sequence data obtained from these genotyping efforts depends on several factors, including the quantity/integrity of the input material, the technology as well as laboratory-specific implementation. The current lack of guidelines for SARS-CoV-2 genotyping leads to inclusion of error-containing genome sequences in genomic epidemiology studies. We aimed at establishing clear and broadly applicable recommendations for reliable virus genotyping. METHODS: We established and used a sequencing data analysis workflow that reliably identifies and removes technical artifacts, which can result in miscalls when using alternative pipelines, to process clinical samples and synthetic viral genomes with an amplicon-based genotyping approach. We evaluated the impact of experimental factors, including viral load and sequencing depth, on correct sequence determination. RESULTS: We found that at least 1000 viral genomes are necessary to confidently detect variants in the SARS-CoV-2 genome at frequencies of 10% or higher. The broad applicability of our recommendations was validated in over 200 clinical samples from six independent laboratories. The genotypes we determined for clinical isolates with sufficient quality cluster by sampling location and period. Our analysis also supports the rise in frequency of 20A.EU1 and 20A.EU2, two recently reported European strains whose dissemination was facilitated by travelling during the summer of 2020. CONCLUSIONS: We present much-needed recommendations for reliable determination of SARS-CoV-2 genome sequence and demonstrate their broad applicability in a large cohort of clinical samples.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family, 2 is at the origin of the pandemic that started at the end of 2019 (1) (2) (3) . Rapid worldwide spread of this 3 pathogen, infecting and killing millions, has led to an unprecedented global effort to characterize the 4 viral genome and track its evolution. This genomic epidemiology work is indispensable for public health 5 monitoring and for high-resolution contact tracing (4,5). The unprecedented extent and speed of SARS-6 CoV-2 genome sequence submissions since the beginning of the pandemic (e.g. 386'000 SARS-CoV-2 7 genomes deposited as of January 2021 (https://www.gisaid.org)) is a testimony to how crucial 8 genotyping has been to understand and control virus transmission. These efforts have been reinforced 9 with the emergence of viral strains with higher transmissibility, such as B.1.1.7 (6), and the need to ensure the efficacy of the vaccines currently deployed against the circulating strains (7).

Rapid increase in the amount of genomic information is inevitably associated with genome submissions 12 of variable quality, depending on the viral load or integrity of the isolate, or data generation and 13 analysis pipelines, for example. Genotyping errors introduced this way can impact the conclusions of 14 downstream analyses (8-10).

Broadly applicable guidelines which consider the sensitivity, specificity and limit of detection of 16 different genotyping approaches are essential to reduce the number of miscalls in SARS-CoV-2 genotypes. Due to their relative low cost and simplicity, amplicon-based methods are the most widely J o u r n a l P r e -p r o o f the assay performance using synthetic reference SARS-CoV-2 genomes. To ensure the wide applicability 3 of our conclusions, we analysed over 200 clinical samples from six independent European laboratories 4 ( Figure 1A) . Our study provides general recommendations for reliable determination of viral genome 5 sequences using amplicon-based methods for SARS-CoV-2 genotyping. (Table S2) . Only samples where the presence of SARS-CoV-2 could be confirmed by qPCR were SOPHiA GENETICS lab performed the test using synthetic SARS-CoV-2 RNA, CDC-USA assay targeting 3 gene N (IDT # 10006713) and One Step PrimeScript™ III RT-PCR Kit (TaKaRa #RR600A) according to 4 manufacturer's instructions.

Benchmarking of SARS-CoV-2 amplicon-based genotyping using synthetic viral genome 8

We established an analysis workflow that detects and removes technical artifacts from sequencing 9 data, a step essential to reduce miscalls introduced by amplification errors and mispriming in 

We utilized synthetic RNA controls to assess how the number of viral genome copies in a sample 16 impacted the quality of the SARS-CoV-2 genotyping results obtained with a commonly used ampliconbased approach (12). We spiked 50 ng of reference human RNA with varying amounts of synthetic SARShuman reads (median 0.03%, Figures 1B and S1F ) supports the specificity of the assay and alleviates 20 the legal, ethical and technical concerns of other methods (3,21). As expected, the total fraction of 21 reads mapped to SARS-CoV-2 genome after read filtering (hereafter 'effective reads') correlated with the number of viral copies in the sample and the yield of amplification of product of the expected size 23 (Figures 1C, S1G and S1H).

Breadth and depth of coverage are critical determinants of genotyping reliability. Both depend on the 1 number of viral genome copies in the input (Figures 2A and S2A) . To establish the depth required to 2 achieve >10x genome coverage across >98% of positions we randomly downsampled reads from samples 3 with 10'000 genome copies per reaction (g.c.p.r.). We found that at least 200K mapped, 150 bp paired-4 end reads are required to achieve these thresholds (Figure 2B ). At this read depth, base coverage was 5 683x on average ( Figure 2C) . No significant improvement in breadth and uniformity of coverage 6 ( Figures 2B and S2B ) was observed for read depths >200K.

For Single Nucleotide Variants (SNVs), 100% sensitivity in clonal variant calling was achieved for read 8 depths above 50K ( Figure 2D ). Presence of a 10-nucleotide deletion, overlapping the annealing site of 9 one of the amplicon primers and leading to a strong decrease in the PCR efficiency ( Figure S2C ), 10 required as much as 800K read depth for detection with 100% sensitivity (Figure 2D ).

The fraction of effective reads is inversely proportional to the number of viral genome copies in the 12 sample. To ensure confident variant calling we recommend genotyping samples with 1000 or more 13 g.c.p.r. Based on the minimal fraction of mapped reads (74%, Figure 2E ) observed for samples with 14 this viral load, we advise sequencing to a depth of at least 280K reads to achieve the recommended 15 minimal depth of >200K reads. The breadth ( Figure S2A ) and uniformity ( Figure S2D ) of coverage for 16 samples with fewer than 1000 viral g.c.p.r. is often lower than recommended and highly variable, 

Next, we aimed to determine the lowest allele fraction which can be confidently measured. We spiked 24 human RNA with predefined mixes of different SARS-CoV-2 synthetic genome strains (totalling 1000 25 g.c.p.r.) to obtain allele fractions between 0.01 and 0.2 (Figure 3A) . At the recommended depth of the VAF of true positives at the expected variant fractions of >0.1 ( Figure 3B ). Variants at VAF of >0.1 1 were detected with at least 95% sensitivity and 95% specificity ( Figure 3C ). The impact of increasing 2 read depth above 200K on the sensitivity and specificity of variant calling was modest (Figure 3D-F) .

Experiments conducted with varying viral loads revealed that 100 g.c.p.r. is insufficient for reliable 4 variant calling at frequencies in a range of 0.1-0.2. Increasing the viral to 10'000 g.c.p.r. did not 5 significantly improve the performance ( Figure S3 ).

In summary, variants at a VAF>0.1 can be confidently detected in samples with 1000 viral genomes or 7 more sequenced to a depth of at least 200K mapped reads.

Since the exact number of viral genomes is often unknown for patient isolates, we next sought to make 10 our guidelines broadly applicable to the analysis of clinical samples. We designed a multicentre study 11 ( Figure 4A and Table S2 ), involving 6 independent European institutions. We left the implementation 12 of the general amplicon-based genotyping protocol (12) to the discretion of each laboratory. The raw 13 sequencing data for 227 clinical samples was processed using our analytical workflow ( Figure S1A) Table S2 ) but restrictions apply to the availability of these data, which were used 5 under license for the current study, and so are not publicly available. Requests must be directed to the 6 owner of each dataset. samples (x-axis). The black horizontal line in the boxplot indicates the median and the whiskers the 5% 23 and 95% quantile. (C) Sensitivity (y-axis) as a function of the specificity (x-axis) with VAF value used as a 24 predictor for true variant calls. The ROC curves are colour coded depending on the expected VAF of the (confidence interval) calculated at 95% specificity (y-axis) and (F) specificity CI at 95% sensitivity (y-axis) 1 as a function the expected VAF for the variant (x-axis). Colour-code for analysis done at different 2 sequencing depths is depicted on the right. 

were classified into three quality categories based on their viral load: good (≥1000 g.c.p.r.), adequate

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses

on data from samples with 10'000 g.c.p.r (D) Average sensitivity of variant calling for SNVs

Error bars represent 13 standard deviation. (E) Percentage of effective reads (Y-axis) shown as a function of the viral load (A) Schematic representation of the experimental design. Varying amounts of SARS-CoV-2 Control 1 or 4 18 (blue) were mixed with SARS-CoV-2 synthetic genome reference (Control 2) to obtain desired VAFs (0.01-19 0.2). 1000 viral genome copy mixes (g.c.p.r.) were spiked into human RNA. Variant calling was performed 20 at varying sequencing depths

blue) and background (false positives, red) variants (y-axis) as a function of the expected VAFs in the (x-axis) is represented in the inset. (C) Fraction of effective reads mapping to the SARS-CoV-2 genome (y-11 axis) as a function of the Ct value of the clinical samples (x-axis). Each point represents the results for a 12 sample colour coded according to the source lab. The percentage of samples with at least 75% effective 13 reads (y-axis) below a given Ct